Tonix Pharmaceuticals Holding Corp TNXP
News
Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA®
Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer
Tonix Pharmaceuticals to Participate in Cantor’s 2026 Global Healthcare Conference
Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights
Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences
Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S.
Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026
